MovDisordV3, PubMed, Corpus, bibRecord, 002839

The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: a double blind placebo-controlled pilot study.

Identifieur interne : 002839 ( PubMed/Corpus ); précédent : 002838; suivant : 002840

The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: a double blind placebo-controlled pilot study.

Auteurs : Tanya Gurevich ; Chava Peretz ; Orna Moore ; Nina Weizmann ; Nir Giladi

Source :

Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2007.

RBID : pubmed:17290455

English descriptors

KwdEn :
- Botulinum Toxins, Type A (administration & dosage), Botulinum Toxins, Type A (therapeutic use), Double-Blind Method, Female, Follow-Up Studies, Humans, Injections, Intramuscular, Leg, Male, Movement Disorders (drug therapy), Movement Disorders (etiology), Muscle, Skeletal, Neuromuscular Agents (administration & dosage), Neuromuscular Agents (therapeutic use), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Pilot Projects, Placebos, Treatment Outcome.
MESH :
- chemical , administration & dosage : Botulinum Toxins, Type A, Neuromuscular Agents.
- chemical , therapeutic use : Botulinum Toxins, Type A, Neuromuscular Agents.
- drug therapy : Movement Disorders, Parkinson Disease.
- etiology : Movement Disorders.
- physiopathology : Parkinson Disease.
- Double-Blind Method, Female, Follow-Up Studies, Humans, Injections, Intramuscular, Leg, Male, Muscle, Skeletal, Pilot Projects, Placebos, Treatment Outcome.

Abstract

To assess the effect on freezing of gait (FOG) of botulinum toxin type A (BTX-A) injections in advanced Parkinson's disease (PD) patients.

DOI: 10.1002/mds.21396
PubMed: 17290455

Links to Exploration step

pubmed:17290455

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: a double blind placebo-controlled pilot study.</title>
<author><name sortKey="Gurevich, Tanya" sort="Gurevich, Tanya" uniqKey="Gurevich T" first="Tanya" last="Gurevich">Tanya Gurevich</name>
<affiliation><nlm:affiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Peretz, Chava" sort="Peretz, Chava" uniqKey="Peretz C" first="Chava" last="Peretz">Chava Peretz</name>
</author>
<author><name sortKey="Moore, Orna" sort="Moore, Orna" uniqKey="Moore O" first="Orna" last="Moore">Orna Moore</name>
</author>
<author><name sortKey="Weizmann, Nina" sort="Weizmann, Nina" uniqKey="Weizmann N" first="Nina" last="Weizmann">Nina Weizmann</name>
</author>
<author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2007">2007</date>
<idno type="doi">10.1002/mds.21396</idno>
<idno type="RBID">pubmed:17290455</idno>
<idno type="pmid">17290455</idno>
<idno type="wicri:Area/PubMed/Corpus">002839</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: a double blind placebo-controlled pilot study.</title>
<author><name sortKey="Gurevich, Tanya" sort="Gurevich, Tanya" uniqKey="Gurevich T" first="Tanya" last="Gurevich">Tanya Gurevich</name>
<affiliation><nlm:affiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Peretz, Chava" sort="Peretz, Chava" uniqKey="Peretz C" first="Chava" last="Peretz">Chava Peretz</name>
</author>
<author><name sortKey="Moore, Orna" sort="Moore, Orna" uniqKey="Moore O" first="Orna" last="Moore">Orna Moore</name>
</author>
<author><name sortKey="Weizmann, Nina" sort="Weizmann, Nina" uniqKey="Weizmann N" first="Nina" last="Weizmann">Nina Weizmann</name>
</author>
<author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2007" type="published">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Botulinum Toxins, Type A (administration & dosage)</term>
<term>Botulinum Toxins, Type A (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Injections, Intramuscular</term>
<term>Leg</term>
<term>Male</term>
<term>Movement Disorders (drug therapy)</term>
<term>Movement Disorders (etiology)</term>
<term>Muscle, Skeletal</term>
<term>Neuromuscular Agents (administration & dosage)</term>
<term>Neuromuscular Agents (therapeutic use)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Pilot Projects</term>
<term>Placebos</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Botulinum Toxins, Type A</term>
<term>Neuromuscular Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term>
<term>Neuromuscular Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Movement Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Double-Blind Method</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Injections, Intramuscular</term>
<term>Leg</term>
<term>Male</term>
<term>Muscle, Skeletal</term>
<term>Pilot Projects</term>
<term>Placebos</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">To assess the effect on freezing of gait (FOG) of botulinum toxin type A (BTX-A) injections in advanced Parkinson's disease (PD) patients.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17290455</PMID>
<DateCreated><Year>2007</Year>
<Month>05</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted><Year>2007</Year>
<Month>07</Month>
<Day>12</Day>
</DateCompleted>
<DateRevised><Year>2010</Year>
<Month>11</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>22</Volume>
<Issue>6</Issue>
<PubDate><Year>2007</Year>
<Month>Apr</Month>
<Day>30</Day>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: a double blind placebo-controlled pilot study.</ArticleTitle>
<Pagination><MedlinePgn>880-3</MedlinePgn>
</Pagination>
<Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the effect on freezing of gait (FOG) of botulinum toxin type A (BTX-A) injections in advanced Parkinson's disease (PD) patients.</AbstractText>
<AbstractText Label="METHOD" NlmCategory="METHODS">BTX-A 150 IU or normal saline was injected into each leg's calf muscles by a blinded investigator. FOG severity was assessed at set intervals (6-month follow-up).</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Eleven age- and disease severity-matched PD patients with disabling FOG participated. Six patients received BTX-A and 5 received saline. No improvement was observed in either group over time. Leg weakness and falls lead to early termination.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">BTX-A injections to the legs did not improve FOG and might increase fall risk.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gurevich</LastName>
<ForeName>Tanya</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Movement Disorders Unit, Parkinson Center, Department of Neurology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Peretz</LastName>
<ForeName>Chava</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Moore</LastName>
<ForeName>Orna</ForeName>
<Initials>O</Initials>
</Author>
<Author ValidYN="Y"><LastName>Weizmann</LastName>
<ForeName>Nina</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y"><LastName>Giladi</LastName>
<ForeName>Nir</ForeName>
<Initials>N</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009465">Neuromuscular Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D010919">Placebos</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.24.69</RegistryNumber>
<NameOfSubstance UI="D019274">Botulinum Toxins, Type A</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019274">Botulinum Toxins, Type A</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005500">Follow-Up Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007273">Injections, Intramuscular</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="Y" UI="D007866">Leg</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009069">Movement Disorders</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018482">Muscle, Skeletal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D009465">Neuromuscular Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010865">Pilot Projects</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010919">Placebos</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year>
<Month>2</Month>
<Day>10</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2007</Year>
<Month>7</Month>
<Day>13</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2007</Year>
<Month>2</Month>
<Day>10</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/mds.21396</ArticleId>
<ArticleId IdType="pubmed">17290455</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002839 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002839 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:17290455
   |texte=   The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: a double blind placebo-controlled pilot study.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:17290455" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: a double blind placebo-controlled pilot study.

The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease: a double blind placebo-controlled pilot study.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki